Pegfilgrastim
Sarcomatoid Renal Cell Carcinoma
Explore 10 assets in Sarcomatoid Renal Cell Carcinoma →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Eastern Cooperative Oncology Group
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00068393CT.gov Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sarcomatoid Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pegfilgrastim (this asset) | Eastern Cooperative Oncology Group | P2 | B · 57 |
| Nivolumab | City of Hope Medical Center | P3 | BB |
| Sorafenib | National Cancer Institute (NCI) | P2 | BB |
| Ipilimumab | City of Hope Medical Center | P3 | BB |
| Cabozantinib | City of Hope Medical Center | P3 | BB |
| Pazopanib | Mayo Clinic | P2 | B |
| Clostridium Butyricum Miyairi 588 | City of Hope Medical Center | P2 | B |
| Adriamycin | Eastern Cooperative Oncology Group | P2 | B |
| Trebananib | National Cancer Institute (NCI) | P2 | B |
+8 more in the Sarcomatoid Renal Cell Carcinoma cohort
Other indications for Pegfilgrastim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neutropenia | — | P4 | BBB · 76 |
| Primary Peritoneal Carcinoma | — | P2/3 | BBB · 73 |
| Diffuse Large B-Cell Lymphoma | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pegfilgrastim in Sarcomatoid Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pegfilgrastim-sarcomatoid-renal-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →